BioSpace News Archive

Ensysce Biosciences Inc. (“Ensysce”), a clinical stage pharmaceutical company developing medicines for severe pain relief to reduce fear of addiction, opioid misuse, abuse and overdose, and Leisure Acquisition Corp. (NASDAQ: LACQ) (“LACQ”) today announced the appointment of David Humphrey to Ensysce’s management team as its Chief Financial Officer.

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its financial results for the full year ended Dec. 31, 2020 after market close on Thursday, Feb. 25, 2021.

Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., will participate in a fireside chat on Friday, February 26, 2021, at the 10th Annual SVB Leerink Global Healthcare Conference.

Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, and the executive management team will participate in a fireside chat at the 10 th Annual SVB Leerink Global Healthcare Conference on February 25,2021

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced completion of submissions for two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for PADCEV®

United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, announced an agreement to offer its suite of cutting-edge Computed Tomography technology to Vizient members at contracted pricing.

-- Conference Call Scheduled for 4:30 p.m. ET -- -- Company to Provide Update on Commercial Launch of Phexxi and Pivotal Phase 3 Trial of EVO100 --

FX received their 510k clearance for the Easytech® Stemless Anatomic. It is the only stemless shoulder prosthesis on the market with primary peripheral fixation.

Thermo Fisher Scientific, the world leader in serving science, today announced it has won six awards in the annual CMO Leadership Awards. The awards, presented by Life Science Leader and Outsourced Pharma, recognize top contract manufacturing partners as evaluated by biopharma and biotech companies.

The Thermo Scientific MAbPac Reversed-Phase Capillary HPLC Columns and Emitters achieve sensitive, reproducible and robust high throughput analysis with minimal sample volume